pharma news today obesity drugs glp-1 september 2025 2024 was a record year for trials and is already poised to take over How Supply and Demand for
Description
By separating obesity and diabetes contexts, and by using active comparators like insulin, metformin, and SGLT2 inhibitors, the study attempted to reduce some of the obvious biases that often weaken retrospective analyses
Analysis of pharmacy claims data from 297,514 members showed that requiring diagnosis codes at point-of-sale effectively controlled both utilization and costs while maintaining appropriate access to medication
Am Heart Assoc 2009
Based on Eli Lilly's public statements and typical FDA timelines, retatrutide approval is most likely in late 2027 or early 2028
Some of the possible complications of gastroparesis can be life-threatening if theyre very severe
